ACOG

Healthcare Biotechnology

Alpha Cognition Inc.

$8.98

-0.17 -1.86% today

Price History

Not enough data

Key Stats

Market Cap

195.57M

Avg Volume

123,849

EPS

-$1.30

52W High

$10.14

52W Low

$4.50

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-14.48

P/B Ratio

3.69

P/S Ratio

12.81

EV/EBITDA

-5.96

EV/Revenue

10.35

Margins

Gross Margin 90.4%

Operating Margin (127.3%)

Net Margin (137.7%)

EBITDA Margin (173.6%)

Growth & Returns

Revenue Growth (YoY)

267.6%

Return on Equity

(49.5%)

Return on Assets

(30.4%)

Liquidity & Leverage

Current Ratio

9.03

Quick Ratio

7.31

Total Cash

41.38M

Total Debt

About

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.